GlassScriptPhysician profile
Nima Sekhadia
NPI 1881058931
$1,664.02
in general payments reported to CMS, 2019-2025
20 companies · $216 in 2025
The $216 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.38 · 2020: $156 · 2021: $481 · 2022: $182 · 2023: $194 · 2024: $378 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749 · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.27 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $268.07 | 2019-2024 | Bexsero |
| Tris Pharma INC | $221.88 | 2019-2022 | |
| Cranial Technologies, INC | $185.02 | 2020-2025 | Doc Band |
| Krystal Biotech INC | $174.84 | 2024-2025 | Vyjuvek |
| Merck Sharp & Dohme LLC | $155.02 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $88.05 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $76.37 | 2024 | Daybue |
| Genentech USA, INC. | $75.58 | 2020-2021 | |
| Sanofi Pasteur INC. | $71.01 | 2019-2023 | |
| Kaleo, INC. | $61.35 | 2021-2022 | |
| Sobi, INC | $45.66 | 2021-2023 | |
| Avion Pharmaceuticals | $42.70 | 2023 | Methylphenidate Hydrochloride |
| Ultragenyx Pharmaceutical INC. | $39.92 | 2021 | |
| Chiesi USA, INC. | $39.00 | 2024 | Filsuvez |
| Supernus Pharmaceuticals, INC. | $25.46 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $22.39 | 2021 | |
| Corium, LLC | $19.70 | 2021 | |
| Biomarin Pharmaceutical INC. | $18.17 | 2025 | Voxzogo 1.2mg |
| Ironshore Pharmaceuticals INC. | $18.01 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Sekhadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.